within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AX28_Levomilnacipran;

model Levomilnacipran
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.92,
    Cl = 6.083333333333333e-06,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.387,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01933333333333333,
    Tlag = 15.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Levomilnacipran</td></tr><tr><td>ATC code:</td><td>N06AX28</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>387</td><td>L</td></tr>
    <tr><td>clearance:</td><td>21.9</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder (MDD) in adults. It is the more active enantiomer of milnacipran and is approved for use in several countries, including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after administration of oral levomilnacipran extended release. Data are based on population PK analysis in both male and female adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AX28 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Levomilnacipran;
